New drug study aims to understand how liver disease affects medication
NCT ID NCT06825559
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This early-stage study will test a drug called saroglitazar magnesium in 6 adults with moderate liver scarring (cirrhosis) caused by cholestatic liver disease. The main goal is to see how the drug moves through the body and if it is safe when taken every other day. Participants will take the drug by mouth and have their blood tested regularly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLESTATIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zydus Site US001
RECRUITINGIndianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vitamin d cocktail fix deficiency in kids with liver disease?
- New drug shows promise for babies with rare liver disorders
- Liver drug study seeks to understand how body processes medication in scarred livers
- Gene hunt for mysterious adult liver disease
- Liver drug maralixibat tested for Long-Term safety in rare disease patients
- Special milk powder aimed to help sick infants – but study never started